Docetaxel-estramustine in high-risk localized prostate cancer: First results of the French Genitourinary Tumor Group phase III trial (GETUG 12).Karim Fizazi, Stéphane Culine, Loı̈c Mourey et al.|Journal of Clinical Oncology|2011Cited by 9
[Randomized placebo trial of myeloprotection with goralatide in patients with squamous cell carcinoma of the upper respiratory and digestive tracts or esophagus, treated with a carboplatin-fluorouracil combination].P Cappelaere, Patrice Carde, B Hecquet et al.|PubMed|1995Cited by 4
[Predictive value of the hemogram for myelotoxicity induced by the association of carboplatin-fluorouracil on the 4th day of the therapeutic regimen].P Cappelaere, B Hecquet, C. Fournier et al.|PubMed|1996Cited by 0
Modelling relapse in patients with high-risk localised prostate cancer treated randomly in the GETUG 12 phase III trial reveals two populations of relapsing patientsCécile Vicier, Karim Fizazi, Laurence Faivre et al.|Annals of Oncology|2016Cited by 0